Wall Street analysts forecast that Cardlytics Inc (NASDAQ:CDLX) will announce sales of $43.81 million for the current quarter, Zacks reports. Six analysts have issued estimates for Cardlytics’ earnings, with the highest sales estimate coming in at $44.70 million and the lowest estimate coming in at $43.10 million. Cardlytics reported sales of $35.57 million in the same quarter last year, which indicates a positive year over year growth rate of 23.2%. The company is expected to issue its next earnings results before the market opens on Tuesday, August 13th.

On average, analysts expect that Cardlytics will report full-year sales of $187.30 million for the current fiscal year, with estimates ranging from $183.00 million to $195.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $255.42 million, with estimates ranging from $245.40 million to $279.08 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.31. The company had revenue of $35.99 million during the quarter, compared to analysts’ expectations of $36.11 million. Cardlytics had a negative return on equity of 84.02% and a negative net margin of 25.53%. Cardlytics’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business posted ($0.35) EPS.

Several research analysts have commented on CDLX shares. Bank of America reaffirmed a “buy” rating and set a $90.00 price target (down previously from $95.00) on shares of Hexcel in a research report on Wednesday. SunTrust Banks restated a “buy” rating and issued a $25.00 price target on shares of Cardlytics in a research note on Tuesday, May 21st. Zacks Investment Research downgraded Phoenix New Media from a “hold” rating to a “sell” rating in a research report on Tuesday. KeyCorp boosted their target price on Harsco from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, May 10th. Finally, ValuEngine upgraded Xylem from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $26.43.

In other Cardlytics news, COO Lynne Marie Laube sold 4,200 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $30.00, for a total transaction of $126,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Scott D. Grimes sold 6,000 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 496,515 shares of company stock worth $12,928,556. 21.90% of the stock is currently owned by company insiders.

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC raised its position in shares of Cardlytics by 2.3% during the 1st quarter. SG Americas Securities LLC now owns 61,277 shares of the company’s stock worth $1,014,000 after purchasing an additional 1,402 shares during the period. BlackRock Inc. raised its position in shares of Cardlytics by 0.4% during the 4th quarter. BlackRock Inc. now owns 422,718 shares of the company’s stock worth $4,578,000 after purchasing an additional 1,610 shares during the period. CIBC Private Wealth Group LLC raised its position in shares of Cardlytics by 6.7% during the 1st quarter. CIBC Private Wealth Group LLC now owns 37,745 shares of the company’s stock worth $624,000 after purchasing an additional 2,375 shares during the period. Bank of America Corp DE raised its position in shares of Cardlytics by 0.9% during the 4th quarter. Bank of America Corp DE now owns 270,025 shares of the company’s stock worth $2,924,000 after purchasing an additional 2,471 shares during the period. Finally, New York State Common Retirement Fund increased its position in Cardlytics by 80.0% in the 4th quarter. New York State Common Retirement Fund now owns 9,000 shares of the company’s stock valued at $97,000 after acquiring an additional 4,000 shares during the period. Institutional investors and hedge funds own 73.51% of the company’s stock.

CDLX stock traded up $0.55 during trading on Monday, hitting $29.06. 212,763 shares of the company’s stock were exchanged, compared to its average volume of 319,938. The firm’s 50-day moving average price is $26.74. The firm has a market capitalization of $655.88 million, a PE ratio of -13.58 and a beta of 1.75. Cardlytics has a 52-week low of $9.80 and a 52-week high of $30.38. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.37 and a quick ratio of 2.37.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Preferred Stock

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.